Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to MDCO
- Medicines Co. (MDCO) Releases Phase III Data for CHAMPION Program of Cangrelor
- The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI
- Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Medicines (MDCO) Posts Q3 Loss of $0.06
More News related to Earnings
- Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
- SkyPeople (SPU) Acquires Yingkou Trusty Fruits in $3.3M Transaction
- GE (GE) Said to Restart NBC Universal Acquisition Talks -WSJ
- Diedrich Coffee (DDRX) Comments on Green Mountain Coffee Roasters' (GMCR) Revised Offer
- Peet's (PEET) Issues Statement Following News Diedrich (DDRX) Says Green Mountain (GMCR) Revised Offer is 'Superior'
The Medicines Company (NASDAQ: MDCO) reports Q3 EPS of $0.06, versus the analyst estimate of ($0.05). Revenue for the quarter was $98.80 million, which compares to the estimate of $96.99 million.
Related Categories
EarningsStocks Mentioned
+0.48Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
